智通财经APP获悉，周二，Senti Biosciences(SNTI.US)开盘涨超7%，报2.54美元。消息面上，Senti Bio报告了更新的1期SENTI-202在R/R AML中的数据，显示50%的总缓解率(ORR)、42%的完全缓解/部分血液学缓解(CR/CRh)，且大多数为微小残留病阴性(MRD-Negative)持久应答，并获得RMAT支持以推进至关键研究。
智通财经APP获悉，周二，Senti Biosciences(SNTI.US)开盘涨超7%，报2.54美元。消息面上，Senti Bio报告了更新的1期SENTI-202在R/R AML中的数据，显示50%的总缓解率(ORR)、42%的完全缓解/部分血液学缓解(CR/CRh)，且大多数为微小残留病阴性(MRD-Negative)持久应答，并获得RMAT支持以推进至关键研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.